Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care
Partnership will focus on developing FoundationOne®CDx as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828 January 19, 2023 07:03 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced a global collaboration with Boehringer Ingelheim to develop the company’s…